Cargando…
Fluids in Sepsis and Septic Shock (FISSH): protocol for a pilot randomised controlled trial
INTRODUCTION: Observational evidence suggests physiological benefits and lower mortality with lower chloride solutions; however, 0.9% saline remains the most widely used fluid worldwide. Given uncertainty regarding the association of lower chloride on mortality, it is unlikely that practice will cha...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642672/ https://www.ncbi.nlm.nih.gov/pubmed/28729329 http://dx.doi.org/10.1136/bmjopen-2017-017602 |
_version_ | 1783271418189840384 |
---|---|
author | Rochwerg, Bram Millen, Tina Austin, Peggy Zeller, Michelle D’Aragon, Frédérick Jaeschke, Roman Masse, Marie-Hélène Mehta, Sangeeta Lamontagne, Francois Meade, Maureen Guyatt, Gordon Cook, Deborah J |
author_facet | Rochwerg, Bram Millen, Tina Austin, Peggy Zeller, Michelle D’Aragon, Frédérick Jaeschke, Roman Masse, Marie-Hélène Mehta, Sangeeta Lamontagne, Francois Meade, Maureen Guyatt, Gordon Cook, Deborah J |
author_sort | Rochwerg, Bram |
collection | PubMed |
description | INTRODUCTION: Observational evidence suggests physiological benefits and lower mortality with lower chloride solutions; however, 0.9% saline remains the most widely used fluid worldwide. Given uncertainty regarding the association of lower chloride on mortality, it is unlikely that practice will change without direct randomised clinical trial (RCT) evidence. This pilot RCT will investigate the feasibility of a large-scale trial directly comparing low chloride with high chloride fluids in patients with septic shock. METHODS AND ANALYSIS: This is a randomised, concealed, blinded parallel-group multicentre pilot trial. We will include adult critically ill patients with septic shock, defined as ongoing hypotension despite 1 L of fluid, or a serum lactate >4 mmol/L, who are within 6 hours of hospital presentation or rapid response team activation. We will exclude patients if they have an aetiology of shock other than sepsis, if they have acute burn injury, elevated intracranial pressure, intent to withdraw life support or previous enrolment in this or a competing trial. Following informed consent, patients will be randomised to a low chloride fluid strategy or a high chloride fluid strategy for the duration of their ICU stay or until 30 days postrandomisation. Clinicians, patients, families and research staff will be blinded. The primary outcome for this trial will be feasibility, assessed by consent rate, recruitment success and protocol adherence. Patient-important clinical outcomes include mortality, receipt of renal replacement therapy, intensive care unit and hospital lengths of stay and surrogate outcomes of incidence of acidosis, hyperkalaemia and acute kidney injury. ETHICS AND DISSEMINATION: This pilot trial will test the feasibility of conducting the main trial, which will examine the effect of high versus low chloride fluids in patients with septic shock on patient-important outcomes. TRIAL REGISTRATION NUMBER: NCT02748382, registered 8 April 2016. PROTOCOL DATE: 1 July 2016. |
format | Online Article Text |
id | pubmed-5642672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-56426722017-10-25 Fluids in Sepsis and Septic Shock (FISSH): protocol for a pilot randomised controlled trial Rochwerg, Bram Millen, Tina Austin, Peggy Zeller, Michelle D’Aragon, Frédérick Jaeschke, Roman Masse, Marie-Hélène Mehta, Sangeeta Lamontagne, Francois Meade, Maureen Guyatt, Gordon Cook, Deborah J BMJ Open Intensive Care INTRODUCTION: Observational evidence suggests physiological benefits and lower mortality with lower chloride solutions; however, 0.9% saline remains the most widely used fluid worldwide. Given uncertainty regarding the association of lower chloride on mortality, it is unlikely that practice will change without direct randomised clinical trial (RCT) evidence. This pilot RCT will investigate the feasibility of a large-scale trial directly comparing low chloride with high chloride fluids in patients with septic shock. METHODS AND ANALYSIS: This is a randomised, concealed, blinded parallel-group multicentre pilot trial. We will include adult critically ill patients with septic shock, defined as ongoing hypotension despite 1 L of fluid, or a serum lactate >4 mmol/L, who are within 6 hours of hospital presentation or rapid response team activation. We will exclude patients if they have an aetiology of shock other than sepsis, if they have acute burn injury, elevated intracranial pressure, intent to withdraw life support or previous enrolment in this or a competing trial. Following informed consent, patients will be randomised to a low chloride fluid strategy or a high chloride fluid strategy for the duration of their ICU stay or until 30 days postrandomisation. Clinicians, patients, families and research staff will be blinded. The primary outcome for this trial will be feasibility, assessed by consent rate, recruitment success and protocol adherence. Patient-important clinical outcomes include mortality, receipt of renal replacement therapy, intensive care unit and hospital lengths of stay and surrogate outcomes of incidence of acidosis, hyperkalaemia and acute kidney injury. ETHICS AND DISSEMINATION: This pilot trial will test the feasibility of conducting the main trial, which will examine the effect of high versus low chloride fluids in patients with septic shock on patient-important outcomes. TRIAL REGISTRATION NUMBER: NCT02748382, registered 8 April 2016. PROTOCOL DATE: 1 July 2016. BMJ Publishing Group 2017-07-20 /pmc/articles/PMC5642672/ /pubmed/28729329 http://dx.doi.org/10.1136/bmjopen-2017-017602 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Intensive Care Rochwerg, Bram Millen, Tina Austin, Peggy Zeller, Michelle D’Aragon, Frédérick Jaeschke, Roman Masse, Marie-Hélène Mehta, Sangeeta Lamontagne, Francois Meade, Maureen Guyatt, Gordon Cook, Deborah J Fluids in Sepsis and Septic Shock (FISSH): protocol for a pilot randomised controlled trial |
title | Fluids in Sepsis and Septic Shock (FISSH): protocol for a pilot randomised controlled trial |
title_full | Fluids in Sepsis and Septic Shock (FISSH): protocol for a pilot randomised controlled trial |
title_fullStr | Fluids in Sepsis and Septic Shock (FISSH): protocol for a pilot randomised controlled trial |
title_full_unstemmed | Fluids in Sepsis and Septic Shock (FISSH): protocol for a pilot randomised controlled trial |
title_short | Fluids in Sepsis and Septic Shock (FISSH): protocol for a pilot randomised controlled trial |
title_sort | fluids in sepsis and septic shock (fissh): protocol for a pilot randomised controlled trial |
topic | Intensive Care |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642672/ https://www.ncbi.nlm.nih.gov/pubmed/28729329 http://dx.doi.org/10.1136/bmjopen-2017-017602 |
work_keys_str_mv | AT rochwergbram fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial AT millentina fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial AT austinpeggy fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial AT zellermichelle fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial AT daragonfrederick fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial AT jaeschkeroman fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial AT massemariehelene fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial AT mehtasangeeta fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial AT lamontagnefrancois fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial AT meademaureen fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial AT guyattgordon fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial AT cookdeborahj fluidsinsepsisandsepticshockfisshprotocolforapilotrandomisedcontrolledtrial |